These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28709554)

  • 1. Lessons Learned from Two Decades of Anticancer Drugs.
    Liu Z; Delavan B; Roberts R; Tong W
    Trends Pharmacol Sci; 2017 Oct; 38(10):852-872. PubMed ID: 28709554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
    Kong D; Yamori T
    Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of mouse tumour models in the discovery and development of anticancer drugs.
    Ireson CR; Alavijeh MS; Palmer AM; Fowler ER; Jones HJ
    Br J Cancer; 2019 Jul; 121(2):101-108. PubMed ID: 31231121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
    Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
    Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
    [No Abstract]   [Full Text] [Related]  

  • 6. Developmental Phases of Anticancer Screening Models.
    Alsamman K; El-Masry OS
    Comb Chem High Throughput Screen; 2017; 20(5):440-450. PubMed ID: 28025935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel drugs for promising targets.
    Martell RE; Brooks DG; Wang Y; Wilcoxen K
    Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
    Suggitt M; Bibby MC
    Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X; Wang Z
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse tumour models to guide drug development and identify resistance mechanisms.
    Das Thakur M; Pryer NK; Singh M
    J Pathol; 2014 Jan; 232(2):103-11. PubMed ID: 24122209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical screening methods in cancer.
    Kumar S; Bajaj S; Bodla RB
    Indian J Pharmacol; 2016; 48(5):481-486. PubMed ID: 27721530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived xenografts as tools in pharmaceutical development.
    Izumchenko E; Meir J; Bedi A; Wysocki PT; Hoque MO; Sidransky D
    Clin Pharmacol Ther; 2016 Jun; 99(6):612-21. PubMed ID: 26874468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
    Fredriksson A; Stone-Elander S
    Methods Mol Med; 2003; 85():279-94. PubMed ID: 12710215
    [No Abstract]   [Full Text] [Related]  

  • 17. New cast for a new era: preclinical cancer drug development revisited.
    Herter-Sprie GS; Kung AL; Wong KK
    J Clin Invest; 2013 Sep; 123(9):3639-45. PubMed ID: 23999436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and evaluation of anticancer agents.
    Zee-Cheng RK; Cheng CC
    Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the development of hybrid anticancer drugs.
    Fortin S; Bérubé G
    Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.
    Naik RR; Singh AK; Mali AM; Khirade MF; Bapat SA
    Oncogene; 2016 Feb; 35(6):727-37. PubMed ID: 25915841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.